Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06967519
PHASE4

OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa

Sponsor: Yale University

View on ClinicalTrials.gov

Summary

A longitudinal study with four parallel cohorts with each participant followed for 2 years: two cohorts in Busia (high malaria transmission site) and two cohorts in Kampala (low malaria transmission). Each site will have a cohort of children living with HIV (CLHIV) and HIV- uninfected children and will be age-matched, enrolled in parallel, and followed for two years. All children will be enrolled without malaria infection, as determined by a negative blood smear at baseline.

Key Details

Gender

All

Age Range

5 Years - 17 Years

Study Type

INTERVENTIONAL

Enrollment

380

Start Date

2025-12-18

Completion Date

2027-12

Last Updated

2026-02-04

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

Artemether-lumefantrine (AL)

Participants will receive the dispersible formulation of AL with contains 20 mg artemether, 120 mg of lumefantrine

DRUG

artesunate-amodiaquine (AS-AQ)

Children will receive the tablet formulations of Artesunate Amodiaquine using weight based dosing

Locations (2)

Baylor- Uganda

Kampala, Uganda

Infectious Disease Research Collaboration (IDRC)

Kampala, Uganda